Clinical Trial Update: SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)

View source ↗

Summary

Post-marketing surveillance study of piribedil (PIR-002/K) in Parkinson's disease to monitor safety and efficacy; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Piribedil (piribedil)

Snippet

Sponsor: Desitin Arzneimittel GmbH | Conditions: Parkinson's Disease | Status: COMPLETED